Metropolis Healthcare Ltd Q2 FY2024 Concall Summary

Key Takeaways

• Core revenue grew 13.4% YoY, driven entirely by 10.4% patient volume growth and a ~3% product-mix lift; price increases were deliberately deferred to prioritize volumes.
• Competitive intensity is easing: new entrants, under margin pressure, are cutting discounts and raising prices, while Metropolis’s sticky, quality-driven “head” of the business (80% of revenue) remains insulated.
• A one-time whistleblower provision of INR3.34 crores and the expiry of a profitable government PPP contract combined to drag reported EBITDA margin to 24.3%, masking underlying gross margin expansion.
• Hitech Diagnostics is integrating well: revenue grew 17% in H1, margins have expanded by a few hundred basis points since acquisition, and a 50-center expansion is planned by next year-end.
• What to watch next quarter: whether the mid-teen H2 growth target materializes as dengue cases rise and deferred September revenue books in Q3, and if the promised price increase materializes in early CY24.

Competitive Moat & Market Structure

• Sticky “head” vs. churning “tail”: 80% of B2B semi-specialized business is stable and quality-driven, with doctors directing patients to trusted labs for critical illnesses; the remaining 20% tail is price-sensitive and churning, which management is de-prioritizing.
• Competitor retreat: new entrants are under margin pressure, forcing them to reduce discounts, cut marketing budgets, and increase prices; they are finding little traction outside metro towns, especially as the post-COVID wellness surge settles.
• B2B resilience: B2B revenue grew 12% YoY without significant dilution, even as competitive intensity focused on this channel; B2B accounts for less than 10% of total revenue.
• B2C momentum: B2C revenues rose 16% YoY, lifting B2C contribution from 47% to 52%; Mumbai B2C grew 23% despite new competition.
• Unorganized sector reality: 85% of the industry remains unorganized, and consumers often cannot distinguish quality; regulation would raise costs for smaller players and benefit compliant chains like Metropolis.

Ameera Shah: "If regulation were to come in it would — could be very beneficial to organizations like us who are already following all the compliances and practices. And actually, it would create a burden on smaller companies to now come up to a certain quality, which means that we would possibly see a reduction in the number of players or at least an increased cost in their operations, which would not then allow them to spoil the market with very, very poor price."

Margin Walk & One-Time Headwinds

• Reported EBITDA margin fell to 24.3% from 27% YoY, with ~2.5% of the decline tied to three discrete items: lab expansion intensity, negative operating leverage from the PPP contract loss, and a one-time INR3.34 crore provision for doubtful debt.
• Gross margin actually expanded: 80% of the gain came from shedding the PPP contract, which carried higher material costs; the remaining 20% came from price negotiation and operational efficiency.
• Creditors declined as a percent of sales because Metropolis made prearrangements with vendors: quicker payment in exchange for higher discounts, particularly on materials, which helped stabilize gross margin.
• Full-year margin guide: EBITDA margins this year will be similar to last year; the 1.2% dilution from lab expansion is the sole reason margins are not at 26.5%–27%.
• New lab margin curve: labs opened after April 2022 contributed 4% of revenues and volumes; management believes they can reach company-level margin in approximately 24 months.

Ameera Shah: "The government business was never our interest, frankly. This particular contract we did for the last five years, more because it was specialized tests, it was profitable and practices were in line with us."

Whistleblower Complaint & Governance

• Complaint received regarding accounting adjustments in debtors accounts for FY22–FY23 and the current financial year; referred to an expert third-party auditor whose report was submitted to the Audit Committee on November 4, 2023.
• Three employees were found to have passed accounting entries totaling INR9.28 crores; a one-time provision of INR3.34 crores was made in Q2 FY24.
• Scope contained: the issue was found in only one region; the employees were separated with immediate effect.
• Revenue restatement query unresolved: an analyst noted that reported Q2 FY23 revenue of INR300.35 crore now shows as INR277 crore; management said they would clarify after the call but did not confirm or deny a restatement on the call.

Hitech Diagnostics Integration

• H1 performance: revenue grew 17% YoY, volumes rose 14%, and EBITDA margin expanded by a few hundred basis points since acquisition, despite unexpected first-year challenges including unethical competitor brand infringement and poaching.
• Synergies captured: integration into parent Metropolis has delivered procurement efficiency, logistics optimization, manpower management, and marketing leverage.
• Network build-out: added more than 35 centers, taking the total to 80 across Chennai; introduced new models including B2B testing, curated wellness, and home testing.
• Forward plan: expand specialty business beyond routine and semi-specialized B2C; add 50 more centers by next year-end; strengthen corporate B2B; expand franchise network across Tamil Nadu; leverage local Metropolis-Hitech synergies to expand margins further.

Network Expansion & Growth Levers

• Lab and center rollout: 12 labs added in H1; plan to add 30 labs this year and 30 in FY25, plus 800 collection centers this year and 800 next year; town count to reach ~600 by year-end from 488.
• Post-FY25 pivot: lab expansion will slow down, and collection center expansion will become more aggressive; management expects margin expansion each year after FY25 as operating leverage kicks in.
• Premium wellness: fastest-growing segment at 27% YoY; contribution rose from 13% to 14% of revenue.
• Specialized testing: revenue grew 12% YoY, with B2C specialized testing up 18%; a dedicated sales team now focuses on specialty portfolios.
• North region: revenue grew 15% YoY, outpacing competition.
• Seeding cities recalibration: seeding-city revenue growth has lagged focus cities because management prioritized other cities and new markets; definitions will be recalibrated at year-end.

Guidance & Commitments

Key Metrics